Triple threat: new combo aims to tackle tough breast cancer
NCT ID NCT06889688
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a combination of three drugs—camrelizumab, apatinib, and eribulin—works better than standard chemotherapy for advanced triple-negative breast cancer. The study will enroll 246 women aged 18 to 70. Researchers will measure how long the cancer stays under control and overall survival, while also checking side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab, apatinib, and eribulin
What this could lead to
If successful, this combination could offer a new, more effective treatment option for advanced triple-negative breast cancer, potentially extending life and improving quality of life.
What could go wrong
This is a Phase 3 trial, but the combination may cause more side effects than standard chemo, and it's not yet proven to work better. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital of Shanghai
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, China
Contact
Contact Phone: •••-•••-••••
-
The Central Hospital Of Yong Zhou
RECRUITINGYongzhou, Hunan, China
Contact Phone: •••-•••-••••
Contact
-
Wuhan Union Hospital of China
NOT_YET_RECRUITINGWuhan, Hubei, China
Contact
Contact Phone: •••-•••-••••
-
Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact
Contact Phone: •••-•••-••••
-
Yichang Central People's Hospital
RECRUITINGYichang, Hubei, China
Contact
Contact Phone: •••-•••-••••